ARCT
- Arcturus Therapeutics Holdings Inc.
()
Overview
Company Summary
Arcturus Therapeutics Holdings Inc. (ARCT) is a biotechnology company that specializes in the development of RNA medicines. Their focus is on creating innovative therapies using messenger RNA (mRNA) technology to treat various diseases.
ARCT is at the forefront of developing mRNA-based vaccines and therapeutics that can potentially revolutionize the way we approach healthcare. mRNA is a type of genetic material that carries instructions for protein synthesis in our cells. Arcturus utilizes this technology to design and develop medicines that target specific disease-causing proteins.
The company's proprietary STARR� (Self-Amplifying RNA) technology platform allows for efficient production of mRNA-based medicines. It enables the genetic instructions to be amplified within the body, resulting in enhanced protein expression and potentially more potent therapeutic effects.
Arcturus Therapeutics has multiple programs in its pipeline, focusing on a range of diseases including rare genetic disorders, respiratory and viral infections, liver diseases, and oncology. They collaborate with various pharmaceutical partners to accelerate the development and commercialization of their mRNA therapeutics.
In addition to their proprietary mRNA platform, the company also provides contract development and manufacturing organization (CDMO) services. Through their subsidiary, Arcturus Therapeutics Ltd., they offer expertise in RNA manufacturing for other biotechnology and pharmaceutical companies.
Overall, Arcturus Therapeutics Holdings Inc. is dedicated to advancing the field of RNA medicines by developing innovative mRNA-based therapies to address unmet medical needs and improve patients' lives.